University of Ioannina
Radiation-driven cross presentation and STING activation enhance CAR T Cell therapy in a murine lymphoma model
Abstract
dc:descriptionCD19-targeted chimeric antigen receptor (CAR) T cells have transformed the treatment of patients with relapsed or refractory CD19-positive hematologic malignancies. However, a significant subset of these patients either fails to respond or eventually relapses and, often has symptomatic disease that requires some form of treatment to support them during the manufacture period of CAR T cells. Radiotherapy (RT) is an established curative and palliative cancer treatment which promotes immunologically mediated tumor cell death. We investigated how RT could be applied prior to CAR T cell therapy to enhance its efficacy. We used mice models bearing two A20 lymphoma tumors, one treated with RT and one without. We found that CAR T cells when administrated with RT exhibited improved control of the abscopal, non-RT-treated tumor. More CAR T cells infiltrated both tumors of the group treated with RT and CAR T cells, whereas antigen specific T cells and adoptive T cell transfer therapy validated upregulated cross presentation in the same group. RT induced activation of the cGAS/STING pathway which was directly associated with the enhanced CAR-T cell anti-tumor effects. Overall, these results suggest RT may serve as optimal adjuvant and bridging therapy in the context of CAR T cell therapy.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kostopoulos, Nektarios
- Κωστόπουλος, Νεκτάριος
Subjects
dc:subject × 11Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55934